Immunology Devices Panel meeting
This article was originally published in The Gray Sheet
Executive Summary
FDA advisory panel meeting August 19 in Rockville, Maryland to discuss draft guidances on anti-nuclear antibodies, anti-thyroid antibodies, and alpha-fetaprotein for neural tube defects. The panel will also discuss points-to-consider documents on "immunohistochemical antibody products and tumor markers (carcinoembryonic antigen, alphafetaprotein, and prostate specific antigen) for monitoring." The panel's agenda also includes open and closed discussion on "pending or future device applications." For more information, contact Peter Maxim at 301/594-1293
You may also be interested in...
Executives On The Move: Changes At The Top At Enzolytics, Dyne Therapeutics And Seres Therapeutics
Recent moves in the industry include new chief financial officers at LENZ Therapeutics and Botanix Pharmaceuticals, plus new chief medical officers at Vigil Neuroscience and Voyager Therapeutics.
Israel's Gamida Cell Survives By Selling To Lender
Having finally secured US approval for Omisirge, Gamida was hoping to bag a strategic partner for the cell therapy. A year on, no suitable partner has been identified and the firm is delisting from the NASDAQ and going private.
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.